▶ 調査レポート

IBD(潰瘍性大腸炎及びクローン病)治療の世界市場:薬物クラス別、病気徴候別、流通経路別

• 英文タイトル:IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market (Drug Class: TNF Inhibitors, Aminosalicylates, Integrin Antagonists, and Corticosteroids; Disease Indication: Ulcerative Colitis and Crohn’s Disease; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Transparency Market Researchが調査・発行した産業分析レポートです。IBD(潰瘍性大腸炎及びクローン病)治療の世界市場:薬物クラス別、病気徴候別、流通経路別 / IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market (Drug Class: TNF Inhibitors, Aminosalicylates, Integrin Antagonists, and Corticosteroids; Disease Indication: Ulcerative Colitis and Crohn’s Disease; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 / TPM-2JN114資料のイメージです。• レポートコード:TPM-2JN114
• 出版社/出版日:Transparency Market Research / 2019年11月7日
• レポート形態:英文、PDF、195ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥857,660 (USD5,795)▷ お問い合わせ
  Multi User¥1,301,660 (USD8,795)▷ お問い合わせ
  Corporate License¥1,745,660 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートはIBD(潰瘍性大腸炎及びクローン病)治療の世界市場について調査・分析し、序論、仮定・研究方法、エグゼクティブサマリー、市場動向、薬物クラス別分析、病気徴候別分析、流通経路別分析、地域別(北米、欧州、アジア太平洋、中南米、中東・アフリカ)分析、競争状況などを含め、次の構成でお届けいたします。
・序論
・仮定・研究手法
・エグゼクティブサマリー
・市場動向
・IBD(潰瘍性大腸炎及びクローン病)治療の世界市場:薬物クラス別
・IBD(潰瘍性大腸炎及びクローン病)治療の世界市場:病気徴候別
・IBD(潰瘍性大腸炎及びクローン病)治療の世界市場:流通経路別
・IBD(潰瘍性大腸炎及びクローン病)治療の世界市場:地域別(北米、欧州、アジア太平洋、中南米、中東・アフリカ)
・IBD(潰瘍性大腸炎及びクローン病)治療の北米市場動向
・IBD(潰瘍性大腸炎及びクローン病)治療の欧州市場動向
・IBD(潰瘍性大腸炎及びクローン病)治療のアジア太平洋市場動向
・IBD(潰瘍性大腸炎及びクローン病)治療の中南米市場動向
・IBD(潰瘍性大腸炎及びクローン病)治療の中東・アフリカ市場動向
・競争状況

Several ongoing drug development projects signify increased reliability of patients on inflammatory bowel disease (IBD) treatment. Based on disease indication, a study published by Transparency Market Research (TMR) reported that, therapeutics for ulcerative colitis are projected to have a relatively wider patient pool than Crohn’s disease, and that their collective sales will reflect on the healthy growth of the IBD (ulcerative colitis and Crohn’s disease) treatment market.

Numerous non-profit institutions along with the governments of various regions are found taking initiatives to educate individuals regarding IBD through campaigns and workshops, which is progressively increasing the patient base for the IBD (ulcerative colitis and Crohn’s disease) treatment market. Besides the informative approach of public organizations, privately-held pharmaceutical companies sense the lucrative landscape that the IBD treatment market is, and are making profits by addressing unmet treatment needs through the development of effective therapeutics.

In the future, the recent development of anti-adhesion molecules will serve as an open ground for market players to introduce new formulations, and target patients who fail to respond to traditional therapeutics. That being said, considering the underlying opportunities that market players are likely to explore to remain as patient-centric as possible, the TMR study projects an above-average growth of the IBD (ulcerative colitis and Crohn’s disease) treatment market, at an estimated CAGR of ~6% during 2019-2027

In the era where consumers tend to resonate more with online distribution channels, surprisingly, ~76% of the total sales of IBD treatment therapeutics are projected to arrive from retail pharmacies, in 2019, which was ~75% in 2018, and is likely to grow to ~78% by 2027. The limited popularity of online pharmacies narrows down to warning letters issued by the U.S. Food and Drug Administration Agency regarding potentially dangerous prescription drugs sold by some rogue online channels. However, a wide distribution network, 24X7 accessibility of retail pharmacies, and one-to-one consultation in cases of absence of primary care are the key influencers leading to high sales, implying that, a distribution partnership with these channels could amplify sales prospects.

The IBD (ulcerative colitis and Crohn’s disease) treatment market in North America is driven by continuous development led by key pharmaceutical companies, as well as increased government funding to underpin the development of better therapeutics. Key companies operating in the region are focusing on the development of branded drugs, while trends reported in TMR’s study suggest that, developing countries in Asia Pacific will witness an increase in the development of biosimilar products. In order to ensure the efficiency of these drugs, several countries such as Australia, Japan, India, China, South Korea, and Malaysia are establishing regulatory norms and testing standards for the approval of biosimilar products.

レポート目次

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market

4. Market Overview

4.1. Introduction

4.2. Key Industry Developments

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, 2017–2027

5. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market, Key Insights

5.1. Clinical Trial Pipeline Analysis: IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market

5.2. Disease Prevalence: IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market

5.3. Major Deals & Strategic Alliances Analysis: IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market

6. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast, by Drug Class

6.1. Key Findings

6.2. Introduction

6.3. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027

6.3.1. TNF Inhibitors

6.3.2. Aminosalicylates

6.3.3. Integrin Antagonists

6.3.4. Corticosteroids

6.3.5. Others

6.4. Market Attractiveness Analysis, by Drug Class

7. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecasts, by Disease Indication

7.1. Key Findings

7.2. Introduction

7.3. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027

7.3.1. Ulcerative Colitis

7.3.2. Crohn’s Disease

7.4. Market Attractiveness Analysis, by Disease Indication

8. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecasts, by Distribution Channel

8.1. Key Findings

8.2. Introduction

8.3. Market Value (US$ Mn) Forecast by Distribution Channel, 2019–2027

8.3.1. Hospital Pharmacies

8.3.2. Retail Pharmacies

8.3.3. Online Pharmacies

8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecasts, by Region

9.1. Key Findings

9.2. Global Market Scenario

9.3. Market Value (US$ Mn) Forecast, by Region, 2019–2027

9.3.1. North America

9.3.2. Europe

9.3.3. Asia Pacific

9.3.4. Latin America

9.3.5. Middle East & Africa

9.4. Market Attractiveness Analysis, by Region

10. North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast

10.1. Key Findings

10.2. Market Value (US$ Mn) Forecast, by Country, 2019–2027

10.2.1. U.S.

10.2.2. Canada

10.3. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027

10.3.1. TNF Inhibitors

10.3.2. Aminosalicylates

10.3.3. Integrin Antagonists

10.3.4. Corticosteroids

10.3.5. Others

10.4. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027

10.4.1. Ulcerative Colitis

10.4.2. Crohn’s Disease

10.5. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019–2027

10.5.1. Hospital Pharmacies

10.5.2. Retail Pharmacies

10.5.3. Online Pharmacies

10.6. Market Attractiveness Analysis

10.6.1. By Country

10.6.2. By Drug Class

10.6.3. By Disease Indication

10.6.4. By Distribution Channel

11. Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast

11.1. Key Findings

11.2. Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2027

11.2.1. Germany

11.2.2. U.K.

11.2.3. France

11.2.4. Italy

11.2.5. Spain

11.2.6. Rest of Europe

11.3. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027

11.3.1. TNF Inhibitors

11.3.2. Aminosalicylates

11.3.3. Integrin Antagonists

11.3.4. Corticosteroids

11.3.5. Others

11.4. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027

11.4.1. Ulcerative Colitis

11.4.2. Crohn’s Disease

11.5. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019–2027

11.5.1. Hospital Pharmacies

11.5.2. Retail Pharmacies

11.5.3. Online Pharmacies

11.6. Market Attractiveness Analysis

11.6.1. By Country/Sub-region

11.6.2. By Drug Class

11.6.3. By Disease Indication

11.6.4. By Distribution Channel

12. Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast

12.1. Key Findings / Developments

12.2. Market Overview

12.3. Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2027

12.3.1. China

12.3.2. India

12.3.3. Japan

12.3.4. Australia & New Zealand

12.3.5. Rest of Asia Pacific

12.4. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027

12.4.1. TNF Inhibitors

12.4.2. Aminosalicylates

12.4.3. Integrin Antagonists

12.4.4. Corticosteroids

12.4.5. Others

12.5. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027

12.5.1. Ulcerative Colitis

12.5.2. Crohn’s Disease

12.6. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019–2027

12.6.1. Hospital Pharmacies

12.6.2. Retail Pharmacies

12.6.3. Online Pharmacies

12.7. Market Attractiveness Analysis

12.7.1. By Country/Sub-region

12.7.2. By Drug Class

12.7.3. By Disease Indication

12.7.4. By Distribution Channel

13. Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast

13.1. Key Findings / Developments

13.2. Market Overview

13.3. Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2027

13.3.1. Brazil

13.3.2. Mexico

13.3.3. Rest of Latin America

13.4. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027

13.4.1. TNF Inhibitors

13.4.2. Aminosalicylates

13.4.3. Integrin Antagonists

13.4.4. Corticosteroids

13.4.5. Others

13.5. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027

13.5.1. Ulcerative Colitis

13.5.2. Crohn’s Disease

13.6. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019–2027

13.6.1. Hospital Pharmacies

13.6.2. Retail Pharmacies

13.6.3. Online Pharmacies

13.7. Market Attractiveness Analysis

13.7.1. By Country/Sub-region

13.7.2. By Drug Class

13.7.3. By Disease Indication

13.7.4. By Distribution Channel

14. Middle East and Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast

14.1. Key Findings / Developments

14.2. Market Overview

14.3. Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2027

14.3.1. GCC Countries

14.3.2. South Africa

14.3.3. Rest of Middle East and Africa

14.4. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027

14.4.1. TNF Inhibitors

14.4.2. Aminosalicylates

14.4.3. Integrin Antagonists

14.4.4. Corticosteroids

14.4.5. Others

14.5. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027

14.5.1. Ulcerative Colitis

14.5.2. Crohn’s Disease

14.6. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019–2027

14.6.1. Hospital Pharmacies

14.6.2. Retail Pharmacies

14.6.3. Online Pharmacies

14.7. Market Attractiveness Analysis

14.7.1. By Country/Sub-region

14.7.2. By Drug Class

14.7.3. By Disease Indication

14.7.4. By Distribution Channel

15. Competition Landscape

15.1. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Share, by Company, 2018

15.2. Market Player – Competition Matrix (By Tier and Size of companies)

15.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)

15.3.1. Pfizer, Inc.

15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.1.2. Product Portfolio

15.3.1.3. SWOT Analysis

15.3.1.4. Strategic Overview

15.3.2. Janssen Biotech, Inc. (Johnson & Johnson)

15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.2.2. Product Portfolio

15.3.2.3. SWOT Analysis

15.3.2.4. Financial Overview

15.3.2.5. Strategic Overview

15.3.3. Valeant Pharmaceuticals International, Inc.

15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.3.2. Product Portfolio

15.3.3.3. SWOT Analysis

15.3.3.4. Financial Overview

15.3.3.5. Strategic Overview

15.3.4. Allergan plc.

15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.4.2. Product Portfolio

15.3.4.3. SWOT Analysis

15.3.4.4. Financial Overview

15.3.4.5. Strategic Overview

15.3.5. Takeda Pharmaceutical Company Limited.

15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.5.2. Product Portfolio

15.3.5.3. SWOT Analysis

15.3.5.4. Financial Overview

15.3.5.5. Strategic Overview

15.3.6. AbbVie, Inc.

15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.6.2. Product Portfolio

15.3.6.3. SWOT Analysis

15.3.6.4. Financial Overview

15.3.6.5. Strategic Overview

15.3.7. Novartis AG

15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.7.2. Product Portfolio

15.3.7.3. SWOT Analysis

15.3.7.4. Financial Overview

15.3.7.5. Strategic Overview

15.3.8. UCB Inc.

15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.8.2. Product Portfolio

15.3.8.3. SWOT Analysis

15.3.8.4. Financial Overview

15.3.8.5. Strategic Overview

15.3.9. Biogen Inc.

15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.9.2. Product Portfolio

15.3.9.3. SWOT Analysis

15.3.9.4. Financial Overview

15.3.9.5. Strategic Overview

List of Tables

Table 01: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 02: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 03: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 04: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 05: North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 06: North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 07: North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 08: North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 09: Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 10: Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 11: Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 12: Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 13: Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 14: Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 15: Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 16: Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 17: Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 18: Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 19: Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 20: Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

Table 21: Middle East & Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 22: Middle East & Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

Table 23: Middle East & Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2027

Table 24: Middle East & Africa IBD (Ulcerative Colitis & Crohn's Disease) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027